BCG-033

N/A

Report date: 2026/04/15 20:02:38
First In Class

Base Information

Drug NameBCG-033
Drug Alias NameBCG033BCG-033
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody +[4] 
Mechanisms of ActionAnti-PTK7Anti-Trop-2DNA topoisomerase I inhibitors
TargetsProtein-tyrosine kinase 7Tumor-associated calcium signal transducer 2DNA topoisomerase I
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsColorectal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBiocytogen Pharmaceuticals (Beijing) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBiocytogen Pharmaceuticals (Beijing) Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsColorectal Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A